GLP-1
A pathway involved in appetite, fullness and glucose regulation. Researchers examine its contribution to the investigational medicine’s overall effects.


INVESTIGATIONAL WEIGHT-LOSS SCIENCE
Three pathways. Metabolic research. Clear expectations.
Retatrutide is an investigational peptide that activates GLP-1, GIP and glucagon receptors. Researchers are studying this three-pathway approach for weight loss and metabolic health. Clinical-trial findings do not make it an approved treatment or an available Body Alchemy Direct offering.
Retatrutide is not offered through Body Alchemy Direct. It is not FDA-approved, and FDA states that it cannot be used in compounding under federal law.
Triple-pathway science
Weight-loss research
Metabolic health
Body-composition research
A CLOSER LOOK
GLP-1, GIP and glucagon receptor activity is being studied together. A 2023 phase 2 trial assessed weight change and adverse events over 48 weeks [1]; this remains research, not a Body Alchemy Direct treatment offer.
A pathway involved in appetite, fullness and glucose regulation. Researchers examine its contribution to the investigational medicine’s overall effects.
An incretin pathway involved in glucose-dependent insulin signaling. Its role is studied alongside GLP-1 and glucagon receptor activity.
A pathway involved in energy and glucose metabolism. Its contribution does not justify promises of muscle preservation or superior results.
Clinical-trial outcomes depend on the studied population and protocol. They are not guaranteed personal results or claims for a compounded product.
* Trial follow-up periods are not a personal treatment schedule. No 1–12-week result promise or dosing plan is provided.
YOUR QUESTIONS, ANSWERED
It activates three receptor types—GLP-1, GIP and glucagon. This differs from single- or dual-receptor approaches, but does not by itself prove superiority or better tolerance.
A 2023 phase 2 trial reported average weight reduction over 48 weeks, with results differing between study groups [1]. It does not predict an individual outcome or validate a compounded product.
The published trial used a controlled injection protocol and reported gastrointestinal adverse effects. Trial supervision is not proof of routine-use safety; this guide provides no dosing instructions.
No. It is investigational and is not offered here. FDA states that retatrutide cannot be used in compounding under federal law.
KNOW THE SCIENCE. UNDERSTAND THE LIMITS.
Explore the science and learn how currently available care options are evaluated.
Explore the Science
Understand the Evidence
Ask Better Questions
Make Informed Choices
Research
Context
Evidence
Limits
Safety
Questions
Informed
Decisions
* Illustrative vial; not actual dispensed packaging. “Medically Tailored” is artwork wording and does not identify a verified formulation or promise treatment. Body Alchemy Direct does not manufacture, compound or dispense medication. This product is not offered; this page is educational only.